5PSQ-069 Basal cell epithelioma induced by ibrutinib: two case reports
5PSQ-069 Basal cell epithelioma induced by ibrutinib: two case reports
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
BackgroundIbrutinib is a tyrosine kinase inhibitor indicated for treatment of chronic lymphocytic leukaemia (CLL) among other pathologies. In the literature its considered a safe drug, however, one of the adverse reactions described in the data sheet as frequent is non-melanoma skin cancer.PurposeTo describe two cases of basal cell epithelioma (BCE...
Alternative Titles
Full title
5PSQ-069 Basal cell epithelioma induced by ibrutinib: two case reports
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535228
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7535228
Other Identifiers
ISSN
2047-9956
E-ISSN
2047-9964
DOI
10.1136/ejhpharm-2018-eahpconf.423
